Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 24
- Locations
- 1
Study Overview
Brief Summary
The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss. The purpose of this clinical investigation is to generate objective and subjective evidence of the clinical performance and safety of the device.
Detailed Description
The primary objective of this clinical investigation is to demonstrate that the RH210A device provides a clinically meaningful improvement in speech understanding in noise compared with unaided listening in adults with perceived mild-to-moderate hearing loss.
Speech-in-noise performance will be assessed using the BKB-SIN (Australian version), which quantifies the change in signal-to-noise ratio required for sentence recognition. The primary endpoint is defined as the within-subject difference between unaided and RH210 conditions (change in SNR = Unaided - RH210). A successful outcome is defined as a mean improvement of equal to or more than 2 dB in SNR with RH210 compared to unaided listening.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18 years
- •Self-perceived mild-to-moderate hearing difficulties/ hearing loss
- •Competent smartphone use (able to complete self-fitting via the app)
- •Able and willing to provide informed consent
- •HHIA screening consistent with perceived hearing difficulty
- •Willingness and ability to attend two in-person research appointments
- •Ability to operate a SmartPhone
Exclusion Criteria
- •Conductive or mixed hearing loss
- •Occluding cerumen
- •Otologic disease/ active ear pathology
- •Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
- •Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
- •Visible deformity of the ear (congenital or traumatic).
- •Fluid, pus, or blood coming from the ear (e.g., active drainage).
- •Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
- •Any acute or chronic dizziness or vertigo associated with hearing issues.
- •Pain or discomfort in or around the ear.
- •Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
- •Unilateral hearing loss of sudden onset or large asymmetry between ears.
- •Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
- •Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
- •Unilateral hearing loss of sudden onset or large asymmetry between ears